Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL3414861 | 1.00 | MEN1 (0.40) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL14246467 | 0.96 | MEN1 (0.39) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL5118964 | 0.95 | MAPT (0.43) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL7709080 | 0.95 | MEN1 (0.38) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL2533342 | 0.92 | MAPT (0.40) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL6111495 | 0.92 | MEN1 (0.44) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL719493 | 0.92 | MAPT (0.43) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL167628 | 0.91 | MEN1 (0.43) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL6697326 | 0.88 | MEN1 (0.49) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104019 | 0.88 | MEN1 (0.49) | MEN1MAPTKMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101572-A1 | DIHYDROOXADIAZINONE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2024-03-28 | — | — | US | disclosed |
| WO-2023243686-A1 | DIHYDROOXADIAZINONE COMPOUND AND PHARMACEUTICAL USE THEREOF | 日本たばこ産業株式会社 | 2023-12-21 | — | — | WO | disclosed |
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| CN-111741948-B | Saturated ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | 日本烟草产业株式会社 | 2023-11-10 | — | — | CN | disclosed |
| EP-3760619-B1 | SATURATED RING-CONDENSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUND, AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2023-10-25 | — | — | EP | disclosed |
| CN-112673008-B | Hypoxanthine compounds | 橘生药品工业株式会社 | 2023-07-18 | — | — | CN | disclosed |
| CN-110475785-B | Peptide compound, method for producing same, composition for screening, and method for selecting peptide compound | 富士胶片株式会社 | 2023-06-13 | — | — | CN | disclosed |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | FUJIFILM CORPORATION (JP) | 2022-05-03 | — | — | US | disclosed |
| US-20220119355-A1 | SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2022-04-21 | — | — | US | disclosed |
| CN-110023315-B | Novel compound or pharmacologically acceptable salt thereof | 国立研究开发法人理化学研究所 | 2021-11-12 | — | — | CN | disclosed |
| US-5639778-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 1997-06-17 | — | — | US | disclosed |
| US-5612316-A | Fluorosugar derivatives of macrolides | PFIZER INC. (US) | 1997-03-18 | — | — | US | disclosed |
| EP-0690843-A1 | INDOLETETRALINS HAVING DOPAMINERGIC ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 1996-01-10 | — | — | EP | disclosed |
| CN-1097740-A | 3-acyl group-2-oxindole-1-benzamide type prodrugs of antiinflammatory | PFIZER (US) | 1995-01-25 | — | — | CN | disclosed |
| EP-0629208-A1 | FLUOROSUGAR DERIVATIVES OF MACROLIDES | PFIZER INC. (US) | 1994-12-21 | — | — | EP | disclosed |
| WO-1994021608-A1 | INDOLETETRALINS HAVING DOPAMINERGIC ACTIVITY | THE UPJOHN COMPANY (US) | 1994-09-29 | — | — | WO | disclosed |
| US-5281615-A | Hypotensive agents | G. D. SEARLE & CO. (US) | 1994-01-25 | — | — | US | disclosed |
| WO-1993018049-A1 | FLUOROSUGAR DERIVATIVES OF MACROLIDES | PFIZER INC. (US) | 1993-09-16 | — | — | WO | disclosed |
| US-5028710-A | Oxidation of corresponding 3-phenylthio indolizine | SANOFI (FR) | 1991-07-02 | — | — | US | disclosed |
| US-4543353-A | VETERINARY ANTIFERTILITY | FARMITALIA CARLO ERBA S.P.A. (IT) | 1985-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | RORC, RORB, RORA | MEN1 3985/4885MAPT 1809/4885KMT2A 1904/4885 |
| US-20240101572-A1 | DIHYDROOXADIAZINONE COMPOUND AND PHARMACEUTICAL USE THEREOF | PLD2, PLD1, PLD4 | MEN1 2622/4885MAPT 4171/4885KMT2A 2993/4885 |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | VIP, NPPA, NGLY1 | MEN1 329/4885MAPT 3979/4885KMT2A 4395/4885 |
| US-20220119355-A1 | SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | RORC, RORB, RORA | MEN1 3985/4885MAPT 1809/4885KMT2A 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.